spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  prednisone 

 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jun 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Dec 2019
Lannett Receives FDA Approvals For Two Dosage Strengths Of Butalbital, Acetaminophen And Caffeine Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 25 Nov 2019
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Feb 2018
ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2017
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2017
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Feb 2017
FDA Approves EMFLAZA(TM) (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2015
Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Mar 2015
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Feb 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Jun 2014
Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2014
Tokai Pharmaceuticals Appoints John McBride as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Nov 2013
Horizon Pharma and Mundipharma Sign Exclusive Agreement to Commercialize LODOTRA(R) in the Middle East and Africa
Biopharmaceuticals Distribution
 HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 May 2013
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Aug 2012
U.S. FDA Grants Priority Review of ZYTIGA(R) (abiraterone acetate) sNDA for Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2012
Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Aug 2011
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2011
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jul 2010
Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA(R) Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 24 Jun 2010
FDA Approves Merck's DULERA(R) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Apr 2010
Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Mar 2010
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2009
Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2009
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2009
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2009
Cougar Biotechnology Initiates Phase III Trial of CB7630 (Abiraterone Acetate) in Chemotherapy-Nave Castration-Resistant Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2009
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Dec 2008
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jul 2008
GPC Biotech Reports That Marketing Authorization Application for Satraplatin is to Be Withdrawn
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2008
Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in the American Cancer Society's Journal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 21 Apr 2008
Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Apr 2008
Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2008
Barr Launches Generic Fosamax(R) Tablets, 70 mg
Biopharmaceuticals FDA Generics
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jan 2008
Sepracor Acquires Exclusive U.S. Rights to Nycomed's ALVESCO(R) HFA and OMNARIS(TM) AQ Products as Well as Ciclesonide Pipeline
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Lodotra(TM) Shows a Sustained Reduction of Morning Stiffness in Patients with Rheumatoid Arthritis Treated with Lodotra(TM) for 12 Months
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2007
GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2007
Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2007
DOR BioPharma Receives Not Approvable Letter From FDA for orBec(R) for Treatment of Gastrointestinal Graft-versus-Host Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Oct 2007
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
Nitec Pharma Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2007
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2007
GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jul 2007
Marketing Authorization Application for Satraplatin Accepted for Review by the European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jul 2007
FDA Oncologic Drugs Advisory Committee Recommends that FDA Wait for Overall Survival Results from Satraplatin Phase 3 Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2007
Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2007
GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2007
GPC Biotech Announces Partnering Agreement for Satraplatin for Japan with Yakult
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Jun 2007
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2007
Updated Study Results Reinforce Survival Benefit of Taxotere(R) (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2007
FDA Approves Norditropin(R)for Treatment of Short Stature Associated with a Rare Genetic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 21 May 2007
Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Spectrum Pharmaceuticals Announces FDA'S Oncology Drug Advisory Committee to Review Satraplatin for the Treatment of Hormone Refractory Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Apr 2007
FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2007
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Spectrum Pharmaceuticals Announces Satraplatin Data Presentation at the American Society of Clinical Oncology Prostate Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2007
GPC Biotech Launches Expanded Access Program for Oncology Drug Candidate Satraplatin in the U.S.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2007
GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Feb 2007
Spectrum Pharmaceuticals Announces Completion of NDA Filing for Satraplatin for Hormone Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Feb 2007
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2007
Agreement between Ipsen and MSD for the Co-Marketing in France of Adrovance(TM) for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Nov 2006
FDA Accepts DOR BioPharma's NDA Filing for orBec(R)
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 14 Nov 2006
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Oct 2006
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Oct 2006
SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Sep 2006
Spectrum Pharmaceuticals Announces Positive Results of Satraplatin Pivotal Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2006
Pharmion Corporation and GPC Biotech Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2006
NeoRx Corporation (Poniard Pharmaceuticals) Announces Treatment of First Patient With Picoplatin in Phase 1/2 Front-Line Prostate Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2006
Independent Data Monitoring Board Recommends Expedited Interim Analysis of Overall Survival Data for Satraplatin Phase 3 Trial
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 116

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 116 additional stories matching:
prednisone
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!